Business / Finance RSS Feed - Business / Finance

Healthbox closes $7M in funding to execute new business priorities

Today Healthbox announces it has closed $7 million in funding to expand on its accelerator model and launch three new business verticals that will continue to drive actionable innovation through collaboration between entrepreneurs and the healthcare industry. [More]

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941. [More]
Cepheid's revenues increase 16% 106.9 million in first quarter 2014

Cepheid's revenues increase 16% 106.9 million in first quarter 2014

Cepheid today reported revenues for the first quarter of 2014 of $106.9 million, representing growth of 16% from $91.9 million for the first quarter of 2013. Net loss in the first quarter of 2014 was $(9.3) million, or $(0.13) per share, which compares to net income of $0.3 million, or $0.00 per share, in the first quarter of 2013. [More]
FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis plc and Forest Laboratories, Inc. today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. [More]
Actavis to purchase four currently marketed products from Akorn

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development [More]
SCRA Technology Ventures announces sale of Selah Genomics to EKF Diagnostics

SCRA Technology Ventures announces sale of Selah Genomics to EKF Diagnostics

SCRA Technology Ventures today announced that portfolio company Selah Genomics was sold to EKF Diagnostics, a publically-traded UK-based diagnostics firm. Selah, a provider of advanced molecular and genomic diagnostic services, completed the deal today, making it the largest of nine exits out of the SC Launch program since 2006. [More]

OPKO Health enters into definitive agreement to acquire Inspiro Medical

OPKO Health, Inc. has entered into a definitive agreement to acquire Inspiro Medical Ltd., an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices. [More]

Creekridge Capital surpasses previous first quarter record

Creekridge Capital, a nationwide independent vendor financing company, announced they have topped all their previous quarter one records throughout the company history. They have surpassed their previous first quarter record, which was set in 2012, by over 30 percent. [More]

Lending Club announces acquisition of Springstone Financial for $140 million

Lending Club, the nation's leading online credit marketplace, announced today that it has acquired Springstone Financial for a total consideration of $140 million in cash and stock. Springstone provides affordable financing options for consumers looking to finance private education and elective medical procedures through a network of over 14,000 schools and healthcare providers. [More]

YouBeauty partners with Spa Week Media Group to present YOUSPA

YouBeauty, the leading voice focused on personalization in beauty and wellness, has partnered with Spa Week Media Group (Spa Week), creator of the largest spa and wellness event in North America, to present YOUSPA, an integrated media event that educates consumers about the benefits of in-spa nourishment to their personal wellness. [More]
Alcresta signs agreement with CFFT to support nutritional status of people with cystic fibrosis

Alcresta signs agreement with CFFT to support nutritional status of people with cystic fibrosis

Alcresta, a leading medical nutrition company developing innovative enzyme-based products for individuals with unique nutritional needs battling acute conditions or chronic diseases, today announced the company has signed an agreement with Cystic Fibrosis Foundation Therapeutics (CFFT) to accelerate the development of Alcresta's enzyme-based point-of-care products to support the nutritional status of people with cystic fibrosis (CF). [More]

GE announces operating earnings of $3.3 billion in first quarter 2014

GE announced today first-quarter 2014 operating earnings of $3.3 billion, with operating earnings per share of $0.33, down 15% from the first quarter of 2013. [More]

UnitedHealth Group reports strong revenue growth in Q1 2014

UnitedHealth Group today reported first quarter results, highlighted by Optum's strong growth in revenues, operating earnings and revenue backlog and UnitedHealthcare's continued strong, diversified performance despite the negative impacts of newly effective ACA taxes and regulatory provisions and sequestration cuts to Medicare. [More]
FDA grants clearance for Breathe Technologies’ Non-Invasive Open Ventilation System

FDA grants clearance for Breathe Technologies’ Non-Invasive Open Ventilation System

Breathe Technologies, Inc. announced today that the U.S. Food and Drug Administration has granted the fifth 510(k) clearance for its Non-Invasive Open Ventilation System, allowing its use with compressed air supply for non-oxygen dependent patients. [More]
Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma, today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company's amino acid based products to physicians and pharmacies throughout the Middle East. [More]

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing. [More]
College of American Pathologists and ASC sign MOU to advance delivery of cytopathology services

College of American Pathologists and ASC sign MOU to advance delivery of cytopathology services

The College of American Pathologists and the American Society of Cytopathology announced today the signing of a memorandum of understanding (MOU) to collaborate on initiatives to advance the delivery of cytopathology services and improve patient care. [More]
Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]

Hooper Holmes enters into Strategic Alliance Agreement with Clinical Reference Laboratory

Hooper Holmes and Clinical Reference Laboratory, Inc. today announced that they have entered into a Strategic Alliance Agreement under which CRL will become Hooper Holmes' exclusive provider of laboratory testing services and Hooper Holmes will become a member of CRL's preferred provider network for wellness programs. [More]

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. [More]